Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function
Open accessThe DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
The Notch signaling pathway and the delta-like 4 ligand (DLL4) play key roles in embryonic vascular development. Many of the pathways involved in embryonic vascular development also play important roles in tumor angiogenesis. In this study, we assessed the expression of DLL4 in primary renal cancer and investigated the biological function of DLL4 in primary endothelial cells. Using real-time quantitative PCR and in situ hybridization, we showed that the expression of DLL4 was up-regulated within the vasculature of clear cell-renal cell carcinoma almost 9-fold more than normal kidney and was correlated with the expression of vascular endothelial growth factor (VEGF). The expression of DLL4 in endothelial cells was up-regulated by VEGF and basic fibroblast growth factor synergistically, and by hypoxia through hypoxia-inducible factor 1α. Down-regulation of DLL4 expression with RNA interference led to decreased expression of HEY1 and EphrinB2, and the inhibition of endothelial cell proliferation, migration, and network formation, all of which are important processes in tumor angiogenesis. The inhibition of proliferation occurred via the induction of cell cycle arrest in G0-G1 by increased expression of p21 and decreased phosphorylation of retinoblastoma. We conclude that an optimal window of the DLL4 expression is essential for tumor angiogenesis and that selective modulation of the DLL4 expression within human tumors may represent a potential novel antiangiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, Notch ligand Dll4 is upregulated in tumor samples from clear cell renal cell carcinoma patients [135], and inhibiting Dll4 leads to the disruption of tumor vasculature within the TME [136, 137].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [135]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · cited 1×
“Relative quantitation of gene expression was done using the method described by Pfaffl ( 21 ).”
MethodTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · cited 1×
“Tumor angiogenesis is an important process in tumor growth and metastatic progression (1).”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Self-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117 · cited 1×
“Similar phenotypes have been only described for VEGF knockout mice (15, 16).”
BackgroundHeterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628 · cited 1×
“Similar phenotypes have been only described for VEGF knockout mice (15, 16).”
BackgroundMutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., & Linehan, W. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9700 · Cited by 1,529 · cited 1×
“CC-RCC, the most common type of malignant renal tumor, accounting for 70% to 80% of cases (30), occurs in both a hereditary and sporadic form, both of which are associated with mutations in the von Hippel-Lindau (VHL) gene (31, 32).”
BackgroundArtavanis-Tsakonas, S., Matsuno, K., & Fortini, M. E. (1995) · Science · doi:10.1126/science.7716513 · Cited by 1,303
HES and HERP families: Multiple effectors of the notch signaling pathway
Iso, T., Kedes, L., & Hamamori, Y. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10208 · Cited by 1,238
Notch signaling is essential for vascular morphogenesis in mice
Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P., Gallahan, D., Closson, V., Kitajewski, J., Callahan, R., et al. (2000) · Genes & Development · doi:10.1101/gad.14.11.1343 · Cited by 1,060 · cited 1×
“However, overexpression of Notch4 or knockout of Notch1 and Notch4 produces similar phenotypes (43, 44).”
Background
Research works printed but not linked: 1
- Brown D, Jarvis R, Pallotta V, Byrom M, Ford L. RNA interference in mammalian cell culture: design, executin and analysis of the siRNA effect. Ambion TechNotes 2002; 9: 3–5.
Cited by
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
“Studies in vitro have shown that blocking Dll-4 could simultaneously decrease tumor growth and stimulate vascular sprouting and branching to increase tumor angiogenesis, although these new blood vessels formed with inferior morphology and function.(286) Jag-1 is mainly expressed by stem cells that antagonizes Notch si…”
BackgroundHypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,180
“Additionally, the Notch ligand Dll4 is a transcriptional target of both HIF-1α and HIF-2α in the endothelium.(55,63) ECs trailing the leading edge begin to form tubes that extend the existing vascular network.”
BackgroundBlockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Noguera-Troise, I., Daly, C., Papadopoulos, N. J., Coetzee, S., Boland, P., Gale, N. W., Chieh Lin, H., Yancopoulos, G. D., & Thurston, G. (2006) · Nature · doi:10.1038/nature05355 · Cited by 1,032
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.-C., Chanthery, Y., Kowalski, J., Watts, R. J., Callahan, C., Kasman, I., et al. (2006) · Nature · doi:10.1038/nature05313 · Cited by 986
Notch Signaling in Development, Tissue Homeostasis, and Disease
Siebel, C., & Lendahl, U. (2017) · Physiological Reviews · doi:10.1152/physrev.00005.2017 · Cited by 978
Metadata
- Authors
- Patel, N. S., Li, J.-L., Generali, D., Poulsom, R., Cranston, D. W., & Harris, A. L.
- Affiliations
- Churchill Hospital (GB)
- Cancer Research UK (GB)
- Venue
- Cancer Research
- Published
- 2005-10-01
- Volume
- 65
- Issue
- 19
- Pages
- 8690-8697
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2153726848
- Cited by
- 349
- References
- 48
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 5 · 2023: 14 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 14 · 2016: 13 · 2015: 15 · 2014: 25 · 2013: 24 · 2012: 29
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PEARL (University of Plymouth) (submittedVersion)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
- Funders
- Environmental Research and Education Foundation
- Cancer Research UK
- Royal College of Surgeons of England
- European Commission
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- DLL4, tumor angiogenesis, renal cell carcinoma, clear cell renal cell carcinoma, endothelial cells, Notch signaling, vascular endothelial growth factor, basic fibroblast growth factor, hypoxia, hypoxia-inducible factor-1α, Hey1, ephrin-B2, endothelial cell proliferation, cell migration, cell cycle arrest, p21, retinoblastoma protein phosphorylation, anti-angiogenic therapy
- MeSH terms
- Blood Proteins, Calcium-Binding Proteins, Cell Movement, Endothelium, Vascular, Humans, Kidney Neoplasms, Neovascularization, Pathologic, Umbilical Veins, Cell Hypoxia, Up-Regulation, In Situ Hybridization, RNA, Small Interfering, Intercellular Signaling Peptides and Proteins, Endothelial Cells, Cell Growth Processes, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-1208
- The paper
- Patel, N. S., Li, J.-L., Generali, D., Poulsom, R., Cranston, D. W., & Harris, A. L. (2005). Up-regulation of Delta-like 4 Ligand in Human Tumor Vasculature and the Role of Basal Expression in Endothelial Cell Function. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-1208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.